Cellulite Changes: Drugs That Cause or Treat It

What Cellulite Actually Is and Why It Changes

Cellulite is not a disease. It is a normal structural variation in subcutaneous fat compartmentalization, visible as skin dimpling most commonly on the thighs and buttocks. The Nurnberger-Muller classification grades cellulite from 0 (no visible dimpling) to 3 (visible dimpling at rest with raised and depressed areas) [1]. Roughly 85 percent of women older than 20 have some degree of cellulite, compared with fewer than 10 percent of men [2].

The anatomical explanation centers on fibrous septae. In women, these connective-tissue bands run perpendicular to the skin surface, creating chambers that allow fat lobules to herniate upward. Men have septae arranged in a criss-cross pattern that resists herniation [1]. Estrogen, insulin, prolactin, and catecholamines all influence the size of fat lobules and the integrity of septae, which is why cellulite often first appears or worsens during puberty, pregnancy, and menopause [2].

Changes in cellulite appearance can happen over weeks or months. Weight gain expands fat lobules. Weight loss can reduce them but may also thin the dermis, making existing septae more visible. Medications that alter hormone levels, fluid retention, collagen turnover, or fat distribution directly affect how cellulite looks and feels. Understanding which drugs push cellulite in which direction is the first step toward a rational treatment plan.

Drugs That May Worsen Cellulite

Certain medications can increase cellulite visibility by promoting fat accumulation, fluid retention, or dermal thinning. Systemic corticosteroids are the most well-documented offenders. Prolonged use of prednisone or dexamethasone promotes centripetal fat redistribution and thins the dermis by suppressing collagen synthesis [3]. A 2019 review in the British Journal of Dermatology noted that glucocorticoid-induced skin atrophy becomes clinically apparent within 3 to 14 days of potent topical steroid use, and systemic steroids compound the effect across larger body areas [3].

Insulin and insulin-secretagogues (sulfonylureas like glipizide) promote lipogenesis. Patients on these agents may notice increased subcutaneous fat in cellulite-prone regions, particularly when caloric intake exceeds expenditure [4]. Hormonal medications present a more nuanced picture. Combined oral contraceptives containing ethinyl estradiol can increase fluid retention and subcutaneous fat in some women, though data linking them directly to worsened cellulite grading remain limited [2].

Dr. Mathew Avram, director of the Dermatology Laser and Cosmetic Center at Massachusetts General Hospital, has stated: "Cellulite is primarily an anatomical and hormonal phenomenon. Any drug that shifts fat storage patterns or degrades collagen can change its clinical presentation" [5].

Antiretroviral therapy, specifically older protease inhibitors like ritonavir, can cause lipodystrophy with subcutaneous fat redistribution that mimics or worsens cellulite in the thighs and buttocks [6]. Patients on these regimens should be counseled about body composition monitoring.

QWO: The First (and Withdrawn) FDA-Approved Cellulite Drug

In July 2020, the FDA approved collagenase clostridium histolyticum-aaes (QWO) for the treatment of moderate-to-severe cellulite in the buttocks of adult women [7]. QWO worked by enzymatically lysing type I and type III collagen in the fibrous septae responsible for skin dimpling. The drug was injected directly into cellulite dimples across three treatment sessions spaced 21 days apart.

The RELEASE-1 and RELEASE-2 phase 3 trials (combined N=1,820) demonstrated statistically significant improvement in cellulite severity at day 71. In RELEASE-1, 32.4 percent of QWO-treated patients achieved a 2-level composite improvement on the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) compared with 13.9 percent on placebo [7]. RELEASE-2 showed similar separation: 30.1 percent versus 13.5 percent [7].

Despite these results, Endo International withdrew QWO from the U.S. market in 2023. The withdrawal was not due to safety signals. It was a commercial decision tied to low uptake, partially driven by bruising at injection sites that lasted 2 to 3 weeks in most patients [8]. Bruising occurred in over 80 percent of treated subjects, and some patients developed nodularity or skin discoloration lasting several months.

The QWO story illustrates a recurring theme in cellulite therapeutics: treatments with measurable efficacy often carry cosmetic side effects that patients find unacceptable. No replacement injectable has received FDA approval as of May 2026.

Topical Retinoids and Methylxanthines

Two topical drug classes have the strongest published evidence for modestly improving cellulite appearance: retinoids and methylxanthines.

Retinoids work by stimulating dermal collagen production and increasing epidermal thickness. A randomized controlled trial published in the Journal of Cosmetic Dermatology found that 0.3 percent retinol cream applied daily for 6 months produced measurable increases in dermal thickness and improved clinical cellulite appearance compared with vehicle [9]. The mechanism is indirect. Thicker dermis reduces the visibility of herniated fat lobules without altering the septae themselves. Tretinoin (prescription-strength retinoic acid) may produce stronger effects, but no large trial has tested it specifically for cellulite grading [9].

Methylxanthines, primarily caffeine and aminophylline, promote lipolysis by inhibiting phosphodiesterase and increasing cyclic AMP in adipocytes. A systematic review in the Journal of the European Academy of Dermatology and Venereology assessed 67 studies of topical cellulite treatments and found that caffeine-containing formulations showed the most consistent, though modest, reductions in thigh circumference (mean 0.5 to 2.0 cm) over 4 to 12 weeks [10]. The clinical significance of these reductions in terms of visible cellulite grading remains debatable.

Dr. Doris Day, clinical associate professor of dermatology at NYU Langone Health, has noted: "Topical caffeine can temporarily tighten the skin and reduce the look of cellulite, but the effect is superficial and requires continuous use to maintain" [5].

Neither retinoids nor methylxanthines alter the fibrous septae that define cellulite architecture. They are best understood as adjuncts, not definitive treatments.

GLP-1 Receptor Agonists and Body Composition

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant reductions in total body fat, which raises the question of whether they improve cellulite. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9 percent mean body weight loss at 68 weeks versus 2.4 percent with placebo [11]. SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg produced 22.5 percent mean weight loss at 72 weeks [12].

No published trial has used cellulite severity as a primary or secondary endpoint for any GLP-1 agonist. The relationship between weight loss and cellulite is not linear. Moderate fat loss (10 to 15 percent of body weight) tends to reduce lobule herniation and improve skin contour. Excessive fat loss, particularly when lean mass is also lost, can thin the dermis and paradoxically make septae-induced dimpling more pronounced [2].

A secondary analysis of the STEP-3 trial found that semaglutide-treated patients lost a higher proportion of visceral fat compared with subcutaneous fat [13]. Since cellulite is a subcutaneous phenomenon, the selective visceral fat loss seen with GLP-1 agonists may limit their cosmetic impact on cellulite-prone areas. Patients who combine GLP-1 therapy with resistance training to preserve lean mass and dermal thickness may see better cosmetic outcomes, though this hypothesis lacks trial data.

Tirzepatide, a dual GIP/GLP-1 agonist, produces greater total fat loss than semaglutide alone [12]. Whether this translates to different effects on cellulite grading is unknown. Clinicians should set realistic expectations: GLP-1 agonists are obesity and type 2 diabetes medications, not cellulite treatments.

Hormonal Therapies: Estrogen, Progesterone, and Testosterone

Estrogen plays a central role in cellulite pathophysiology. It stimulates lipogenesis in gluteofemoral fat depots, increases ground substance hydration, and may weaken septae over time [2]. This is why cellulite typically worsens during the high-estrogen states of pregnancy and perimenopause (when estrogen fluctuates widely before declining) [14].

Menopausal hormone therapy (MHT) with conjugated estrogens or estradiol replaces declining estrogen but may theoretically worsen cellulite by maintaining estrogen-driven fat compartmentalization. No randomized trial has directly measured cellulite outcomes in women on MHT versus placebo. Observational data from the Women's Health Initiative suggest that conjugated equine estrogen plus medroxyprogesterone acetate increased total body fat by a small but significant amount over 3 years [15].

Testosterone, by contrast, may improve cellulite appearance through two mechanisms: promoting lipolysis in subcutaneous depots and increasing dermal collagen density [14]. Women on low-dose testosterone therapy for hypoactive sexual desire disorder sometimes report improved skin texture as a secondary benefit, though this has not been studied with validated cellulite scales.

Progesterone in isolation has not been linked to cellulite worsening. Some progestins with androgenic activity (norethindrone, levonorgestrel) may actually have mild anti-cellulite effects through androgen receptor activation in adipose tissue, but evidence is limited to case series [14].

Subcision, Energy Devices, and Drug-Device Combinations

While this article focuses on drugs, subcision deserves mention because it directly targets the fibrous septae that no topical or systemic medication can adequately address. The FDA-cleared Cellfina system uses a vacuum-stabilized needle to sever individual septae under local anesthesia. A 5-year follow-up study (N=45) published in Dermatologic Surgery showed that 96 percent of treated patients maintained at least a 1-level improvement on the Cellulite Severity Scale at 5 years post-treatment [16].

Drug-device combination approaches are under investigation. Deoxycholic acid (Kybella), FDA-approved for submental fat, has been studied off-label for cellulite in small pilot trials with mixed results [17]. The concept of combining collagenase injections with radiofrequency or acoustic wave therapy has been explored in preclinical models but lacks human trial data.

Acoustic wave therapy (AWT) alone has modest evidence. A meta-analysis in the Journal of Cosmetic and Laser Therapy (7 RCTs, N=297) found that AWT produced a mean 0.57-point improvement on the Cellulite Severity Scale after 6 to 12 sessions, but effects diminished within 6 months without maintenance sessions [18].

When Cellulite Changes Signal Something Else

Sudden or asymmetric changes in skin texture resembling cellulite can indicate conditions unrelated to cosmetic cellulite. Cellulitis (the infectious condition, not cosmetic cellulite) presents with erythema, warmth, and tenderness, usually unilateral [19]. Lipodermatosclerosis, seen in chronic venous insufficiency, causes skin hardening and dimpling of the lower legs that mimics cellulite but reflects fibrosis from venous hypertension [20].

Inflammatory breast cancer can present as skin dimpling (peau d'orange) that may be mistaken for cellulite. Any new, localized skin dimpling over the breast should prompt urgent evaluation [20]. Lymphedema from surgery, radiation, or infection can cause tissue changes with a cellulite-like appearance, particularly in the thigh.

Drug-induced lipodystrophy, as seen with antiretroviral therapy or long-term corticosteroids, creates fat redistribution patterns that differ from typical cellulite. If skin texture changes are accompanied by fat loss in the face or extremities and fat gain in the trunk, lipodystrophy should be considered [6]. Clinicians should perform a directed history and physical exam when patients report rapid or unusual cellulite changes, particularly when accompanied by pain, warmth, or asymmetry.

A Practical Approach to Managing Drug-Related Cellulite Changes

For patients whose cellulite has worsened on a medication, the first step is determining whether the offending drug can be substituted. Switching from a sulfonylurea to metformin or an SGLT2 inhibitor may reduce insulin-driven lipogenesis [4]. Patients on long-term corticosteroids should be tapered to the lowest effective dose when possible, and topical steroids should be rotated to minimize dermal atrophy [3].

For patients seeking active improvement, a tiered approach works best. Start with topical retinol (0.3 to 1.0 percent) nightly for 3 to 6 months, which carries minimal risk and may thicken the dermis enough to reduce visibility [9]. Add caffeine-based topical formulations for modest circumference reduction [10]. For Nurnberger-Muller grade 2 or 3 cellulite unresponsive to topicals, consider subcision (Cellfina) or consultation with a dermatologist experienced in energy-based devices.

Patients on GLP-1 agonists for obesity should be counseled that weight loss may improve or worsen cellulite appearance depending on the degree of fat loss and lean mass preservation. Resistance training 2 to 3 times per week during GLP-1 therapy helps preserve muscle mass and dermal support [11]. Daily protein intake of 1.2 to 1.6 g per kg of body weight supports this goal.

No topical, injectable, or systemic drug currently available produces complete cellulite resolution. The 2023 American Academy of Dermatology position statement on cellulite recommends setting patient expectations accordingly and combining mechanical, topical, and lifestyle approaches for best results [5].